Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer

BACKGROUND: The very aggressive nature and low survival rate of pancreatic ductal adenocarcinoma (PDAC) dictates the necessity to find novel efficacious therapies. Recent evidence suggests that phosphoinositide 3-kinase (PI3K) and 3-phosphoinositide-dependent protein kinase 1 (PDK1) are key effector...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Exp Clin Cancer Res
मुख्य लेखकों: Emmanouilidi, Aikaterini, Fyffe, Chanse A., Ferro, Riccardo, Edling, Charlotte E., Capone, Emily, Sestito, Simona, Rapposelli, Simona, Lattanzio, Rossano, Iacobelli, Stefano, Sala, Gianluca, Maffucci, Tania, Falasca, Marco
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2019
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6518649/
https://ncbi.nlm.nih.gov/pubmed/31088502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1191-2
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन